R&D channel feed – Endpoints News

R&D channel feed

Relmada's rapid-acting NMDA depression drug expected to fail second Phase 3

5 months ago

As 23andMe struggles, another genetic testing company bets on drug discovery

5 months ago

Atea blueprints Phase 3 for hepatitis C combo after mid-stage win

5 months ago

Lilly beats Novo in bellwether head-to-head weight loss study

5 months ago

GSK terminates Phase 2 trial of HBV therapeutic vaccine

5 months ago

Ipsen secures rights to preclinical T cell engager in $610M pact with French biotech

5 months ago

Cartesian tees up Phase 3 mRNA CAR-T study in myasthenia gravis

5 months ago

Roivant says long-shot drug for a rare lung disease failed its Phase 2 study

5 months ago

Revolution sells $600M in shares on back of RAS inhibitor portfolio updates

5 months ago

Janux soars on early prostate cancer data that could challenge Novartis' Pluvicto

5 months ago

Olema, Novartis ink another agreement, this time for a late-stage breast cancer trial

5 months ago

Novocure says electric field therapy extends life for pancreatic cancer patients by two months

5 months ago

Merus drug shows ‘unexpected improvement’ in second-line head and neck cancer study

5 months ago

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

5 months ago

Applied Therapeutics' rare disease drug gets a CRL

5 months ago

Outlook's shares crash as wet AMD drug flunks Phase 3 test

5 months ago

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

5 months ago

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

5 months ago

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

5 months ago

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

5 months ago

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

5 months ago

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

5 months ago

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

5 months ago

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

5 months ago

First page Previous page 14 15 161718 19 20 Next page Last page